Pluri Has Launched A New Business Division Offering Cell Therapy Manufacturing Services As A Contract Development And Manufacturing Organization, PluriCDMO
Portfolio Pulse from Benzinga Newsdesk
Pluri has announced the launch of PluriCDMO, a new business division focused on providing cell therapy manufacturing services. This move positions Pluri as a Contract Development and Manufacturing Organization (CDMO) within the $5.2 billion cell and gene therapy market. The new division aims to assist companies in developing and manufacturing transformative cell therapies.
January 08, 2024 | 12:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pluri's launch of PluriCDMO could potentially increase revenue streams and market presence in the cell and gene therapy sector, signaling growth opportunities.
The establishment of PluriCDMO directly aligns with Pluri's business expansion and could attract new clients in the cell therapy space, likely leading to increased revenues and positive investor sentiment in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100